Have you heard of the recent regulatory changes surrounding cell and gene therapy (CGT) products in Japan?
These changes have greatly increased the interest in taking CGT clinical programs to Japan from development through commercialization. ISCT (International Society for Cellular Therapy) and FIRM (Forum for Innovative Regenerative Medicine) have created a partnership to facilitate the entry and development of future CGT products in Japan.
Robert Preti, PhD (General Manager of Hitachi Chemical’s Regenerative Medicine Business Sector) and Kazuchika Furuishi, PhD (Deputy General Manager) are joining a leading Japanese management consultant (Colin Novick) to discuss the challenges to consider and examples of solutions for successfully taking your clinical cell or gene therapy program to Japan.
On Wednesday, December 6, the webinar will explore the attractive regulatory changes in Japan, as well as:
- Increased offshore filing activity
- Challenges to consider
- Successful CGT programs brought to Japan